White kidney bean extract (WKBE) and its potential to help lower HbA1c is a question increasingly asked by people managing blood sugar in the UK, particularly those with prediabetes or type 2 diabetes. Derived from Phaseolus vulgaris, WKBE is marketed as a 'carb blocker' that partially inhibits alpha-amylase, the enzyme responsible for breaking down dietary starches. By slowing starch digestion, it may reduce post-meal glucose spikes — a key driver of long-term HbA1c levels. This article examines the evidence, NHS and NICE guidance, safety considerations, and when to seek professional medical advice.

What Is White Kidney Bean Extract and How Does It Work?

White kidney bean extract inhibits alpha-amylase to slow starch digestion, potentially reducing post-meal blood glucose rises. It is a food supplement, not a licensed medicine, and EFSA has not authorised glycaemic health claims for it.

White kidney bean extract (WKBE) is a natural supplement derived from Phaseolus vulgaris, a common legume. It is widely marketed as a 'carb blocker' and is available over the counter in health food shops and online retailers across the UK. The extract has attracted growing interest among people looking to manage their blood sugar levels, weight, or both — particularly those with prediabetes (also referred to in UK clinical practice as non-diabetic hyperglycaemia, or NDH) or type 2 diabetes.

The proposed mechanism of action centres on the inhibition of alpha-amylase, a digestive enzyme produced by the pancreas and salivary glands. Alpha-amylase is responsible for breaking down complex carbohydrates (starches) into simpler sugars that can be absorbed through the gut wall. It is important to note that WKBE acts on starches specifically and does not inhibit the absorption of free sugars (such as glucose, fructose, or sucrose). By partially blocking alpha-amylase, WKBE may reduce the rate and extent of starch digestion, leading to a slower and lower rise in blood glucose following a starchy meal.

This mechanism is broadly similar — though not identical — to that of the prescription medication acarbose, an alpha-glucosidase inhibitor used in some patients with type 2 diabetes. However, WKBE is considerably less potent and its effects are more variable. The active compound responsible for this inhibitory action is a glycoprotein known as phaseolamin. The concentration of phaseolamin can differ significantly between products, and unlike licensed medicines, food supplements are not routinely tested for content accuracy or clinical efficacy before sale. This makes comparing study results and predicting clinical outcomes challenging.

It is also relevant that the European Food Safety Authority (EFSA) has not authorised health claims relating to weight management or glycaemic control for Phaseolus vulgaris extracts, reflecting the insufficient evidence base for such claims. WKBE is classified as a food supplement in the UK, not a licensed medicine, and is therefore not subject to the same regulatory standards as pharmaceutical agents overseen by the Medicines and Healthcare products Regulatory Agency (MHRA). Patients should approach marketing claims with appropriate scepticism and choose products from reputable UK suppliers where possible. Any supplement use should be discussed with a qualified healthcare professional.

The Link Between Carbohydrate Absorption and HbA1c Levels

By reducing postprandial glucose spikes, WKBE could theoretically contribute to lower HbA1c over time, but current evidence from small, short-duration trials is insufficient to confirm a meaningful clinical effect.

HbA1c (glycated haemoglobin) is a blood test that reflects average blood glucose levels over the preceding two to three months. It is the primary marker used by clinicians to diagnose type 2 diabetes, assess non-diabetic hyperglycaemia (NDH, sometimes called prediabetes), and monitor long-term glycaemic control. In line with NICE guidance (NG28), an HbA1c of 48 mmol/mol (6.5%) or above is diagnostic of type 2 diabetes, whilst levels between 42–47 mmol/mol (6.0–6.4%) indicate NDH and a high risk of developing the condition.

It is worth noting that HbA1c can be unreliable in certain circumstances — including in people with anaemia, haemoglobin variants (such as sickle cell trait or thalassaemia), chronic kidney disease (CKD), or during pregnancy. In these situations, alternative glucose-based tests (such as fasting plasma glucose or an oral glucose tolerance test) may be more appropriate, and clinicians will advise accordingly.

Because HbA1c is influenced by sustained blood glucose levels rather than a single reading, interventions that consistently reduce post-meal glucose spikes — known as postprandial hyperglycaemia — have the potential to contribute to a lower HbA1c over time. This is the theoretical basis for interest in WKBE as a supplement for glycaemic management.

Some small-scale clinical trials and systematic reviews have suggested that WKBE supplementation may modestly reduce postprandial blood glucose and, in some cases, fasting glucose levels. A 2020 review published in Nutrients found evidence of modest improvements in glycaemic markers in overweight individuals. However, the evidence base remains limited by:

• Small sample sizes in most trials

• Short study durations (often 4–12 weeks), which are insufficient to reliably assess HbA1c changes

• Heterogeneity in product formulations and phaseolamin concentrations

• Lack of large, well-designed randomised controlled trials (RCTs)

Whilst the mechanistic rationale is plausible, there is currently insufficient robust clinical evidence to confirm that white kidney bean extract meaningfully lowers HbA1c in humans. Any potential benefit is likely to be modest and should not be considered a substitute for established lifestyle or pharmacological interventions.

NHS and NICE Guidance on Supplements for Blood Sugar Management

Neither NICE nor the NHS recommends white kidney bean extract for blood sugar management; evidence-based strategies include structured lifestyle programmes, dietary modification, and metformin where clinically indicated.

Neither the NHS nor the National Institute for Health and Care Excellence (NICE) currently recommends white kidney bean extract as a treatment or management strategy for non-diabetic hyperglycaemia (NDH), type 2 diabetes, or elevated HbA1c. NICE guidelines for type 2 diabetes (NG28) and for preventing type 2 diabetes in people at high risk focus on evidence-based interventions, which include structured lifestyle modification programmes, dietary changes, increased physical activity, and, where appropriate, pharmacological therapy such as metformin.

NICE's guidance on blood glucose management emphasises a whole-diet approach rather than reliance on individual supplements. Dietary strategies with the strongest evidence for improving HbA1c include:

• Reducing overall refined carbohydrate and free sugar intake

• Increasing dietary fibre from wholegrains, legumes, vegetables, and fruit

• Following a Mediterranean-style or low-glycaemic-index diet

• Caloric restriction where weight loss is clinically indicated

The NHS Diabetes Prevention Programme (NHS DPP) offers structured, evidence-based support for people identified as being at high risk of type 2 diabetes — specifically those with an HbA1c of 42–47 mmol/mol (NDH). Referral to this programme is recommended by NICE for eligible individuals and has strong evidence for reducing progression to type 2 diabetes.

Food supplements in the UK are regulated under food law rather than medicines legislation. This means manufacturers are not required to demonstrate clinical efficacy before bringing a product to market. The MHRA can take action if a supplement makes unauthorised medicinal claims or poses a safety risk, but routine pre-market efficacy testing is not mandated. As noted above, EFSA has not authorised health claims for Phaseolus vulgaris extracts in relation to weight management or glycaemic control. Patients should therefore approach marketing claims about WKBE and HbA1c with appropriate caution and always discuss supplement use with a qualified healthcare professional.

Safety Considerations, Side Effects, and Drug Interactions

WKBE commonly causes gastrointestinal side effects such as bloating and flatulence; people taking insulin, sulphonylureas, or acarbose face potential hypoglycaemia risk and should seek medical advice before use.

White kidney bean extract is generally considered to have a favourable short-term safety profile when taken at recommended doses. Because it reduces starch digestion in the small intestine, undigested carbohydrates pass into the large intestine where they are fermented by gut bacteria. This can result in gastrointestinal side effects, particularly during the initial period of use. Commonly reported effects include:

• Flatulence and bloating

• Abdominal discomfort or cramping

• Loose stools or diarrhoea

• Nausea

These effects are typically mild and tend to diminish as the body adjusts. Starting with a lower dose and gradually increasing it may help minimise gastrointestinal symptoms. People with pre-existing gastrointestinal conditions — such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) — should seek medical advice before use, as increased colonic fermentation may exacerbate symptoms.

Of greater clinical concern is the potential for WKBE to interact with prescribed medications. Individuals taking insulin or sulphonylureas (such as gliclazide or glibenclamide) should exercise particular caution, as any additive glucose-lowering effect — however modest — could theoretically increase the risk of hypoglycaemia (low blood sugar). Similarly, those taking acarbose should avoid combining it with WKBE without medical supervision, given the overlapping mechanism of action on carbohydrate digestion.

There is currently no official guidance from the MHRA or EMA specifically addressing WKBE interactions, and long-term safety data in humans remain limited. WKBE is not recommended for use during pregnancy or breastfeeding due to insufficient safety evidence. People with known legume allergies should also avoid this supplement.

If you experience any suspected side effects from WKBE or any other supplement, you can report these to the MHRA via the Yellow Card scheme (yellowcard.mhra.gov.uk). This helps the MHRA monitor the safety of supplements and medicines available in the UK.

It is essential that anyone with a diagnosed metabolic condition, or who is taking prescribed medication for blood sugar management, consults their GP or diabetes care team before starting any new supplement, including white kidney bean extract.

When to Speak to a GP About Managing Your HbA1c

Anyone with an HbA1c of 42 mmol/mol or above, diabetes symptoms, or who is considering supplements alongside prescribed medication should consult their GP promptly rather than self-managing.

If you are concerned about your blood sugar levels or have received an elevated HbA1c result, speaking to your GP is the most important first step. A GP can provide an accurate clinical assessment, rule out underlying causes, and offer personalised guidance based on your full medical history and current medications. Self-managing with supplements alone — without professional oversight — carries the risk of delaying effective treatment.

You should contact your GP promptly if:

• Your HbA1c result is 42 mmol/mol or above, even if you feel well

• You are experiencing symptoms that may suggest high blood sugar, such as increased thirst, frequent urination, unexplained fatigue, or blurred vision

• You have a family history of type 2 diabetes and are concerned about your own risk

• You are already taking medication for diabetes and are considering adding any supplement to your routine

• You experience symptoms of hypoglycaemia (shakiness, sweating, confusion, or palpitations), particularly if you are on glucose-lowering medication

Seek same-day urgent medical attention if you or someone else develops severe symptoms that may indicate significantly elevated blood glucose or diabetic ketoacidosis (DKA), including vomiting, marked drowsiness or confusion, rapid unexplained weight loss, signs of dehydration, or the smell of ketones on the breath. These symptoms require prompt assessment and should not be managed with supplements.

Note that HbA1c is not used for diagnosis during pregnancy or in people with conditions affecting red blood cell turnover or haemoglobin variants. In these circumstances, your GP or diabetes team will use alternative plasma glucose-based tests.

For those with NDH (HbA1c 42–47 mmol/mol), your GP may refer you to the NHS Diabetes Prevention Programme (NHS DPP), which has strong evidence for reducing progression to type 2 diabetes through structured lifestyle support. Dietary advice from a registered dietitian, weight management support, and increased physical activity remain the cornerstones of evidence-based HbA1c management.

Whilst white kidney bean extract may have a modest and plausible mechanistic role in reducing postprandial glucose from starchy foods, it should be viewed — at best — as a supplementary measure within a broader, clinically supervised lifestyle plan. It is not a replacement for medical advice, prescribed treatment, or the well-evidenced dietary and lifestyle strategies recommended by NICE and the NHS.

Frequently Asked Questions